Fannin In-licenses Anti-Neuroinflammation Small Molecule Drugs from University of Nebraska Medical Center 

Houston, TX, June 12, 2020 - Fannin has recently licensed a series of compounds from the University of Nebraska Medical Center (UNMC), with plans to tackle neuroinflammation to treat a wide range of disease states.

 

This series of compounds was developed by Dr. Corey Hopkins, PhD. Dr. Hopkins is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences. His laboratory focuses on developing compounds that can penetrate the blood brain barrier. The laboratory utilizes both computational modeling and small molecule synthesis techniques to optimize and develop structure activity relationships. This series was designed to target specific elements of neuroinflammation.

 

Current data indicates that the lead compound has promising pharmacokinetic properties, including once daily dosing, oral bioavailability, and good brain penetration. This compound is highly selective for its target enzyme without having psychological implications, as confirmed by NIMHs psychoactive screen. These compounds reduce inflammation in the innate immune system. In a proof-of-concept model of cocaine use disorder, the lead compound significantly reduced self-administration.

 

The Goldenrod Therapeutics namesake is an homage to the state flower of its home state, Nebraska. It was originally conceived by Dr. Corey Hopkins at the University of Nebraska Medical Center in Omaha. Fannin Innovation Studio, one of Houston’s leading biotechnology commercialization groups, is pleased to partner with Dr. Hopkins to progress a promising therapeutic to a market that needs it most.

 

 

About Fannin

Houston-based Fannin is an early-stage life sciences development group focused exclusively on commercializing medical technologies. Fannin partners with life science innovators to co-found startup companies by providing a pooled experienced management team, central office space and seed funding. To further bridge the commercialization gap, Fannin’s apprenticeship program provides aspiring entrepreneurs with hands-on development experience with its portfolio companies. For more information, visit www.FanninInnovation.com or email innovate@fannininnovation.com.

 

Previous
Previous

Goldenrod Therapeutics Announces Abstract Accepted for Presentation at The International Society of Addiction Medicine’s (ISAM) 2022 World Congress Meeting

Next
Next

NIH Awards Goldenrod Therapeutics $350,000 to Develop Novel Treatment for Opioid Use Disorder